Browse Studies — Arctuva

Phase 1

A Phase 1a/b, Open-label, Dose-escalation and Dose-expansion, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of MX006 in Patients With Selected Advanced Solid Tumor Types Known to Express B7-H3

This is a Phase 1a/1b, multicenter, open-label, first-in-human (FIH) study with MX006 treatment in patients with selected tumor types known to express B7-H3. T…

Advanced and/or Metastatic Solid Tumors Known to Express B7-H3

Estimated

~$150 – $4,200

Actual pay is set by the research site.